FDA-approved feline diabetes oral liquid med distributes in the U.S.

By /

Diabetic cats and their owners in the U.S. can now have easy access to oral liquid medication.

Senvelgo, which was approved by the U.S. Food and Drug Administration (FDA) last August, has been officially launched and is now available in veterinary clinics across the country. Developed by Boehringer Ingelheim, the oral medication is a liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus.

“Senvelgo oral solution is a game-changer that will revolutionize the management of feline diabetes. It significantly eases the complexity of feline diabetes treatment and is easy to administer,” said Cynthia Ward, VMD, PhD, DACVIM, professor emerita of Internal Medicine at the University of Georgia and member of the U.S. Boehringer Ingelheim Diabetes Advisory Board, in the company’s statement last August. “In addition, Senvelgo oral solution makes it simpler to successfully monitor treatment and makes time-intensive blood glucose curve monitoring redundant.”

Feline diabetes is one of the most common endocrine disorders in cats,1 with studies showing that up to 30 percent of diagnosed cats are left untreated due to the complexities of existing treatments.2 The Boehringer Ingelheim oral solution simplifies the treatment process and removes the need for needles to improve glycemic control in cats with diabetes mellitus not previously treated with insulin.

References

  1. Susan Gottlieb & Jacquie Rand (2018) Managing feline diabetes: current perspectives, Veterinary Medicine: Research and Reports, 9:, 33-42, DOI: 10.2147/VMRR.S125619
  2. Niessen SJM et al., The Big Pet Diabetes Survey: Perceived Frequency and Triggers for Euthanasia. Vet Sci. 2017 May 14;4(2):27.
Scroll to Top